Display Settings:

Format

Send to:

Choose Destination
    Expert Opin Biol Ther. 2009 Mar;9(3):355-68.

    Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.

    Source

    Protein Interactions, CCRNP, NCI-Frederick, NIH, Building 469, 150B, P.O. Box B, Miller Drive, Frederick, MD 21702 1201, USA. prabakaran.ponraj@duke.edu

    Erratum in

    • Expert Opin Biol Ther. 2009 Apr;9(4):533.

    Abstract

    Background: Recently, several potently neutralizing fully human monoclonal antibodies (hmAbs) targeting the severe acute respiratory syndrome-associated coronavirus (SARS CoV) S glycoprotein, and the G glycoprotein of the paramyxoviruses Hendra virus (HeV) and Nipah virus (NiV) have been discovered [corrected]. Objective: To examine, compare and contrast the functional characteristics of hmAbs with the potential for prophylaxis and treatment of diseases caused by SARS CoV, HeV and NiV. Methods: A review of relevant literature. Results/conclusions: Structural, functional and biochemical analyses [corrected] have provided insights into the molecular mechanisms of receptor recognition and antibody neutralization, and suggested that these antibodies alone or in combination could fight the viruses' heterogeneity and mutability, which is a major problem in the development of effective therapeutic agents against viruses, including therapeutic antibodies.

    PMID:
    19216624
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2705284
    Free PMC Article

    Images from this publication.See all images (2) Free text

    Figure 1
    Figure 2

      Supplemental Content

      Icon for Informa Healthcare Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk